2021 ACG临床指南:结直肠癌筛查

2021-03-01 美国胃肠病学院 Am J Gastroenterol . 2021 Mar 1;116(3):458-479.

2021年3月,美国胃肠病学院(ACG)发布了结直肠癌筛查指南,结直肠癌筛查的方向是切除腺瘤和无蒂锯齿状息肉,并检测早期结直肠癌。本文是对2009年指南的更新,主要针对结直肠癌的筛查提供指导建议。

中文标题:

2021 ACG临床指南:结直肠癌筛查

英文标题:

ACG Clinical Guidelines: Colorectal Cancer Screening 2021

发布机构:

美国胃肠病学院

发布日期:

2021-03-01

简要介绍:

2021年3月,美国胃肠病学院(ACG)发布了结直肠癌筛查指南,结直肠癌筛查的方向是切除腺瘤和无蒂锯齿状息肉,并检测早期结直肠癌。本文是对2009年指南的更新,主要针对结直肠癌的筛查提供指导建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 ACG临床指南:结直肠癌筛查.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3fdc31c002069aa6, title=2021 ACG临床指南:结直肠癌筛查, enTitle=ACG Clinical Guidelines: Colorectal Cancer Screening 2021, guiderFrom=Am J Gastroenterol . 2021 Mar 1;116(3):458-479., authorId=0, author=, summary=2021年3月,美国胃肠病学院(ACG)发布了结直肠癌筛查指南,结直肠癌筛查的方向是切除腺瘤和无蒂锯齿状息肉,并检测早期结直肠癌。本文是对2009年指南的更新,主要针对结直肠癌的筛查提供指导建议。, cover=https://img.medsci.cn/2021311/1615392140961_2020535.jpg, journalId=0, articlesId=null, associationId=269, associationName=美国胃肠病学院, associationIntro=美国胃肠病学院(ACG)是公认的胃肠专业教育及大众消化道疾病的领导者。The American Journal of Gastroenterology(AJG)为该学会的官方期刊。, copyright=0, guiderPublishedTime=Mon Mar 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月,美国胃肠病学院(ACG)发布了结直肠癌筛查指南,结直肠癌筛查的方向是切除腺瘤和无蒂锯齿状息肉,并检测早期结直肠癌。本文是对2009年指南的更新,主要针对结直肠癌的筛查提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=539, tagName=结直肠癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=539, guiderKeyword=结直肠癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=30626, appHits=380, showAppHits=0, pcHits=1459, showPcHits=30246, likes=2, shares=21, comments=24, approvalStatus=1, publishedTime=Thu Mar 11 00:10:14 CST 2021, publishedTimeString=2021-03-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Mar 11 00:02:27 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:21:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ACG临床指南:结直肠癌筛查.pdf)])
2021 ACG临床指南:结直肠癌筛查.pdf
下载请点击:
评论区 (21)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1066604, encodeId=6b3a10666043d, content=非常有用!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5475689150, createdName=ms8000000777276112, createdTime=Wed Nov 03 15:34:24 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064056, encodeId=e64210640567a, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:07:09 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064055, encodeId=a32e1064055ac, content=混个积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:04:54 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055271, encodeId=739510552e161, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:16 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055171, encodeId=7b9010551e12d, content=有中文版吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7334261502, createdName=13e813b4m09暂无昵称, createdTime=Sun Sep 26 22:17:11 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-11-03 ms8000000777276112

    非常有用!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1066604, encodeId=6b3a10666043d, content=非常有用!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5475689150, createdName=ms8000000777276112, createdTime=Wed Nov 03 15:34:24 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064056, encodeId=e64210640567a, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:07:09 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064055, encodeId=a32e1064055ac, content=混个积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:04:54 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055271, encodeId=739510552e161, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:16 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055171, encodeId=7b9010551e12d, content=有中文版吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7334261502, createdName=13e813b4m09暂无昵称, createdTime=Sun Sep 26 22:17:11 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-10-26 ms4000000876991867

    积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1066604, encodeId=6b3a10666043d, content=非常有用!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5475689150, createdName=ms8000000777276112, createdTime=Wed Nov 03 15:34:24 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064056, encodeId=e64210640567a, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:07:09 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064055, encodeId=a32e1064055ac, content=混个积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:04:54 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055271, encodeId=739510552e161, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:16 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055171, encodeId=7b9010551e12d, content=有中文版吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7334261502, createdName=13e813b4m09暂无昵称, createdTime=Sun Sep 26 22:17:11 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-10-26 ms4000000876991867

    混个积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1066604, encodeId=6b3a10666043d, content=非常有用!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5475689150, createdName=ms8000000777276112, createdTime=Wed Nov 03 15:34:24 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064056, encodeId=e64210640567a, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:07:09 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064055, encodeId=a32e1064055ac, content=混个积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:04:54 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055271, encodeId=739510552e161, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:16 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055171, encodeId=7b9010551e12d, content=有中文版吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7334261502, createdName=13e813b4m09暂无昵称, createdTime=Sun Sep 26 22:17:11 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-27 病友

    非常棒

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1066604, encodeId=6b3a10666043d, content=非常有用!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5475689150, createdName=ms8000000777276112, createdTime=Wed Nov 03 15:34:24 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064056, encodeId=e64210640567a, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:07:09 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064055, encodeId=a32e1064055ac, content=混个积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdc5630519, createdName=ms4000000876991867, createdTime=Tue Oct 26 13:04:54 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055271, encodeId=739510552e161, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:58:16 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055171, encodeId=7b9010551e12d, content=有中文版吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7334261502, createdName=13e813b4m09暂无昵称, createdTime=Sun Sep 26 22:17:11 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-26 13e813b4m09暂无昵称

    有中文版吗?

    0

拓展阅读

2010 BSG 中高危人群结直肠癌筛查与监测指南

英国胃肠病学会(BSG,British Society of Gastroenterology) · 2010-05-01

2010 结直肠癌肝转移诊断和综合治疗指南(V 2010)

中华医学会外科学分会 · 2010-06-01

2011 NICE 结直肠癌诊疗指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-01-01

2011NICE 结直肠癌高危人群(溃疡性结肠炎、克罗恩病、结直肠腺瘤患者)结肠镜监测指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-03-23

2011 规范结直肠癌术中缓释型氟尿嘧啶腹腔内化疗的专家共识

结直肠癌术中缓释型氟尿嘧啶腹腔内化疗共识专家组 · 2011-06-01

结直肠癌诊疗规范(2010年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-12-20